{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T16:21:54Z","timestamp":1762014114731,"version":"build-2065373602"},"reference-count":19,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiolog\u00eda"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.rx.2019.06.004","type":"journal-article","created":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T07:47:22Z","timestamp":1565336842000},"page":"131-138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Reacciones adversas inmunomediadas como predictoras de respuesta en pacientes oncol\u00f3gicos en tratamiento con inmunoterapia"],"prefix":"10.1016","volume":"62","author":[{"given":"A.","family":"Ezponda Casaj\u00fas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Calvo Imirizaldu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.P.","family":"de Torres Tajes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Garc\u00eda-Baiz\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Casta\u00f1\u00f3n \u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Cano Rafart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Vivas P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Bastarrika Alema\u00f1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rx.2019.06.004_bib0100","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1126\/science.342.6165.1432","article-title":"Breakthrough of the year 2013 Cancer immunotherapy","volume":"342","author":"Couzin-Frankel","year":"2013","journal-title":"Science."},{"key":"10.1016\/j.rx.2019.06.004_bib0105","doi-asserted-by":"crossref","first-page":"992","DOI":"10.2214\/AJR.10.6198","article-title":"Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy","volume":"197","author":"Bronstein","year":"2011","journal-title":"AJR Am J Roentgenol."},{"key":"10.1016\/j.rx.2019.06.004_bib0110","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1158\/2326-6066.CIR-15-0102","article-title":"Radiographic Profiling of Immune-related Adverse Events in Advanced Melanoma Patients Treated With Ipilimumab","volume":"3","author":"Tirumani","year":"2015","journal-title":"Cancer Immunol Res."},{"key":"10.1016\/j.rx.2019.06.004_bib0115","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rx.2019.06.004_bib0120","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J Exp Med."},{"key":"10.1016\/j.rx.2019.06.004_bib0125","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer."},{"key":"10.1016\/j.rx.2019.06.004_bib0130","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immunetherapy activity in solid tumors: immune-related response criteria","volume":"15","author":"Wolchock","year":"2009","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.rx.2019.06.004_bib0135","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1148\/rg.352140121","article-title":"Cancer immunotherapy: Imaging assessment of novel treatment response patterns and immune-related adverse events","volume":"35","author":"Kwak","year":"2015","journal-title":"Radiographics."},{"key":"10.1016\/j.rx.2019.06.004_bib0140","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune Related Adverse Events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rx.2019.06.004_bib0145","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1007\/s10637-017-0534-0","article-title":"Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience","volume":"36","author":"Fujii","year":"2018","journal-title":"Invest New Drugs."},{"key":"10.1016\/j.rx.2019.06.004_bib0150","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center","volume":"33","author":"Horvat","year":"2015","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.rx.2019.06.004_bib0155","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.rx.2019.06.004_bib0160","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1200\/JCO.2014.60.0379","article-title":"Toxicities of immunotherapy for the practitioner","volume":"33","author":"Weber","year":"2015","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.rx.2019.06.004_bib0165","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.rx.2019.06.004_bib0170","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.rx.2019.06.004_bib0175","doi-asserted-by":"crossref","first-page":"567","DOI":"10.2214\/AJR.16.17770","article-title":"Immune Checkpoint Inhibitors in Lung Cancer: Imaging Considerations","volume":"209","author":"Wang","year":"2017","journal-title":"AJR Am J Roentgenol."},{"key":"10.1016\/j.rx.2019.06.004_bib0180","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJMc1505197","article-title":"Anti-PD1 related pneumonitis during cancer inmunotherapy","volume":"373","author":"Nishino","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rx.2019.06.004_bib0185","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","article-title":"Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab","volume":"152","author":"Hua","year":"2016","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.rx.2019.06.004_bib0190","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","article-title":"Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and metaanalysis","volume":"33","author":"Teulings","year":"2015","journal-title":"J Clin Oncol."}],"container-title":["Radiolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033833819301006?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033833819301006?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:44:55Z","timestamp":1758501895000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033833819301006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S0033833819301006"],"URL":"https:\/\/doi.org\/10.1016\/j.rx.2019.06.004","relation":{},"ISSN":["0033-8338"],"issn-type":[{"type":"print","value":"0033-8338"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reacciones adversas inmunomediadas como predictoras de respuesta en pacientes oncol\u00f3gicos en tratamiento con inmunoterapia","name":"articletitle","label":"Article Title"},{"value":"Radiolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rx.2019.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 SERAM. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}